Diabetes Mellitus in Children and Adolescents
Stuart A. Weinzimer,
William V. Tamborlane,
Stuart A. Weinzimer
Yale University School of Medicine, New Haven, CT, USA
Search for more papers by this authorWilliam V. Tamborlane
Yale University School of Medicine, New Haven, CT, USA
Search for more papers by this authorStuart A. Weinzimer,
William V. Tamborlane,
Stuart A. Weinzimer
Yale University School of Medicine, New Haven, CT, USA
Search for more papers by this authorWilliam V. Tamborlane
Yale University School of Medicine, New Haven, CT, USA
Search for more papers by this authorFirst published: 15 January 2004
Abstract
The diagnosis and treatment of diabetes mellitus in children and adolescents present unique challenges to the clinician. Whereas once all children with diabetes were assumed to have type 1 diabetes, the increasing prevalence of type 2 diabetes in the pediatric population complicates both diagnostic and treatment algorithms. The goal of achieving near-normal glucose control in youth demands an approach to treatment that attends to the developmental level of the child and the abilities and resources of the family. New developments in insulin delivery and glucose sensing technologies may improve quality of life and hold the promise of an eventual “artificial pancreas.” This chapter focuses on the specific clinical presentations and differential diagnoses of diabetes mellitus in children, as well as on current approaches to optimal in- and outpatient management of the disease and the incorporation of newer technologies into routine clinical practice.
References
- 1 Sperling MA. Diabetes mellitus. In MA Sperling (ed), Pediatric Endocrinology. Philadelphia: Saunders, 2002; pp 323–66.
- 2 Karvonen M, Vilik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Care 2000; 23: 1516–26.
- 3 Drash A. Diabetes mellitus in the child: classification, diagnosis, epidemiology, and etiology. In F Lifshitz (ed), Pediatric Endocrinology. New York: Marcel Dekker, 1990; pp 663–80.
- 4 Chase HP, Crews KR, Garg S, Crews MJ, Cruickshanks KJ, Klingensmith G, Gay E, Hamman RF. Outpatient management vs. in-hospital management of children with new-onset diabetes. Clin Pediatr 1992; 31: 450–6.
- 5 Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001; 22: 706–17.
- 6 Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142–8.
- 7 Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K, and the Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15: 369–76.
- 8 Murphy NP, Keane SM, Ong KK. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26: 799–804.
- 9 Yki-Jarvinen H, Koivisto VA. Natural course of insulin resistance in type 1 diabetes. N Engl J Med 1986; 315: 224–30.
- 10 The DCCT Research Group. The effect of intensive diabetes treatment in the DCCT on residual insulin secretion in IDDM. Ann Int Med 1998; 128: 517–23.
- 11 Attia N, Caprio S, Jones TW, Heptulla R, Holcombe J, Silver D, Sherwin RS, Tamborlane WV. Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes. J Clin Endocrinol Metab 1999; 84: 2324–8.
- 12 Katz MA. Hyperglycemia-induced hyponatremia. N Engl J Med 1973; 289: 843–4.
- 13 Harris GD, Fiordalisi I, Harris WL, Mosovich LL, Finberg L. Minimizing the risk of brain herniation during treatment of diabetic ketoacidemia: a retrospective and prospective study. J Pediatr 1990; 117: 22–31.
- 14 Harris GD, Fiordalisi I. Physiologic management of diabetic ketoacidemia: a 5-year prospective pediatric experience in 231 episodes. Arch Pediatr Adolesc Med 1994; 148: 1046–52.
- 15 Ham MR, Okada P, White PC. Bedside ketone determination in diabetic children with hyperglycemia and ketosis in the acute care setting. Pediatr Diabetes (in press).
- 16 Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, Kaufman F, Quayle K, Roback M, Malley R, Kuppermann N. Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med 201; 344: 264–9.
- 17 Duck SC, Wyatt DT. Factors associated with brain herniation in the treatment of diabetic ketoacidosis. J Pediatr 1988; 113: 10–4.
- 18 Bello FA, Sotos JF. Cerebral edema in diabetic ketoacidosis in children. Lancet 1990; 336: 64.
- 19 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
- 20 The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177–88.
- 21 White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001; 139: 804–12.
- 22 Grey M, Boland EA, Davidson M, Li J, Tamborlane WV. Coping skills training for youth on intensive therapy has long lasting effects on metabolic control and quality of life? J Pediatr 2000; 137: 107–14.
- 23 Boland EA, Weinzimer SA, Steffen AT, Tamborlane WV. Randomized, prospective trial of CSII vs. MDI with glargine in children: a preliminary report. Diabetes 2003; 52 (suppl 2): A 45.
- 24 Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46: 440–3.
- 25 Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001; 24: 69–72.
- 26 Boland EA, Grey M, Fredrickson L, Tamborlane WV. CSII: a “new” way to achieve strict metabolic control, decrease severe hypoglycemia and enhance coping in adolescents with type I diabetes. Diabetes Care 1999; 22: 1779–894.
- 27 Weinzimer SA, Ahern JH, Boland EA, Steffen AT, Tamborlane WV. Continuous subcutaneous insulin infusion is safe and effective in infants and toddlers. Diabetes 2003; 52 (suppl 2): A 402.
- 28 Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998; 21: 817–21.
- 29 Celona-Jacobs N, Weinzimer SA, Rearson MA, Hartz D, Katz LEL, Murphy K. Insulin pump therapy in children: a cautionary tale. Diabetes 2001; 50 (suppl 2): A 67.
- 30 Bina DM, Anderson RL, Johnson ML, Bergenstal RM, Kendall DM. Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. Diabetes Care 2003; 26: 981–5.
- 31 Boland EA, DeLucia M, Brandt C, Grey MJ, Tamborlane WV. Limitations of conventional methods of self blood glucose monitoring: lessons learned from three days of continuous glucose monitoring in pediatric patients with type I diabetes. Diabetes Care 2001; 24: 1858–62.
- 32 Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, Garg SK. Continuous subcutaneous monitoring in children with type 1 diabetes. Pediatrics 2001; 107: 222–6.
- 33 Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001; 24: 2030–4.
- 34 Chase HP, Roberts MD, Wightman C, Klingensmith G, Garg SK, Van Wyhe M, Desai S, Harper W, Lopatin M, Bartkowiak M, Tamada J, Eastman RC. Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics 2003; 111: 790–4.
- 35 The Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the CGMSTM in children with type 1 diabetes: results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther 2003; 5: 781–9.
- 36 The Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the GlucoWatch® G2TM Biographer in children with type 1 diabetes: results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther 2003; 5: 791–800.
- 37 American Diabetes Association Task Force for Writing Nutrition Principles and Recommendations for the Management of Diabetes and Related Complications. American Diabetes Association position statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. J Amer Diet Assoc 2002; 102: 109–18.
- 38 Gregory RP, Davis DL. Use of carbohydrate counting for meal planning in type 1 diabetes. Diabetes Educ 1994; 20: 406.
- 39 Jones TW, Porter P, David EA, O'Leary P, Frazer F, Byrne G, Stick S, Tamborlane WV. Suppressed epinephrine responses during sleep: a contributing factor to the risk of nocturnal hypoglycemia in insulin-dependent diabetes. N Engl J Med 1999; 338: 1657–62.
- 40 Kordonouri O, Klinghammer A, Lang EB, Gruters-Kieslich A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents with type 1 diabetes. Diabetes Care 2002; 25: 1346–50.
- 41 Freemark M, Levitsky LL. Screening for celiac disease in children with type 1 diabetes: two views of the controversy. Diabetes Care 2003; 26: 1932–9.
- 42 Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report for the national high blood pressure education program. Pediatrics 1996; 98: 649–57.
- 43 American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26: S83–6.
- 44 American Academy of Pediatrics. Cholesterol in childhood. Pediatrics 1998; 101: 141–7.
- 45 Rosenbloom AL, Joe JR, Young RS, Winter WE. The emerging epidemic of type 2 diabetes mellitus in youth. Diabetes Care 1999; 22: 345–54.
- 46 Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 1996; 37: 97–102.
- 47 Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346: 802–10.
- 48 Travers SH, Jeffers BW, Bloch CA, Hill JO, Eckel RH. Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children. J Clin Endocrinol Metab 1995; 80: 172–8.
- 49 Guzzaloni G, Grugni G, Mazzilli G, Moro D, Morabito F. Comparison between beta-cell function and insulin resistance indexes in prepubertal and pubertal obese children. Metabolism 2002; 51: 1011–6.
- 50 Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002; 25: 89–94.
